$0.66
0.78% today
NYSE, Apr 02, 09:20 pm CET
ISIN
US81727U1051
Symbol
SENS

Senseonics Stock price

$0.66
-0.21 23.57% 1M
+0.33 97.24% 6M
+0.14 27.03% YTD
+0.14 27.01% 1Y
-1.28 65.73% 3Y
+0.10 16.92% 5Y
-2.59 79.54% 10Y
NYSE, Closing price Tue, Apr 01 2025
+0.01 1.34%
ISIN
US81727U1051
Symbol
SENS
Sector

Key metrics

Market capitalization $433.42m
Enterprise Value $457.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.35
P/S ratio (TTM) P/S ratio 19.29
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 0.37%
Revenue (TTM) Revenue $22.47m
EBIT (operating result TTM) EBIT $-74.84m
Free Cash Flow (TTM) Free Cash Flow $-62.70m
Cash position $74.91m
EPS (TTM) EPS $-0.13
P/E forward negative
P/S forward 12.29
EV/Sales forward 12.97
Short interest 7.09%
Show more

Is Senseonics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Senseonics Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Senseonics forecast:

2x Buy
40%
1x Hold
20%
2x Sell
40%

Analyst Opinions

5 Analysts have issued a Senseonics forecast:

Buy
40%
Hold
20%
Sell
40%

Financial data from Senseonics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
22 22
0% 0%
100%
- Direct Costs 22 22
14% 14%
98%
0.53 0.53
83% 83%
2%
- Selling and Administrative Expenses 33 33
14% 14%
146%
- Research and Development Expense 41 41
16% 16%
183%
-73 -73
1% 1%
-327%
- Depreciation and Amortization 1.48 1.48
16% 16%
7%
EBIT (Operating Income) EBIT -75 -75
1% 1%
-333%
Net Profit -79 -79
30% 30%
-350%

In millions USD.

Don't miss a Thing! We will send you all news about Senseonics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Senseonics Stock News

Neutral
Seeking Alpha
30 days ago
Senseonics Holdings, Inc. (NYSE:SENS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Rick Sullivan - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Matt Taylor - Jefferie...
Neutral
GlobeNewsWire
30 days ago
Received FDA approval for Eversense ®  365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia
Neutral
GlobeNewsWire
about one month ago
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system
More Senseonics News

Company Profile

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Head office United States
CEO Timothy Goodnow
Employees 117
Founded 2014
Website www.senseonics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today